Results 21 to 30 of about 16,411 (192)

Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]

, 2020
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A, Camm, JA, Deneault-Marchand, A, Fox, KAA, Gobeil, F, Mansour, S, Matteau, A, Potter, BJ   +7 more
core   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis

Medicines, 2023
Background: Edoxaban is a novel oral anticoagulant which may decrease the risk of stroke and systemic embolism in patients suffering from atrial fibrillation (AF).
Yapeng Wang, Li Li, Zhanlan Wei, Shan Lu, Wenxue Liu, Janghui Zhang, Junbo Feng, Dongjin Wang   +7 more
doaj   +1 more source

Update on Extended Treatment for Venous Thromboembolism [PDF]

, 2018
The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge, Demelo-Rodríguez, Pablo, Llamazares-Mendo, Cristina, Marra, Alberto M, Peñaloza-Martínez, Eduardo, Proietti, Marco, Soria Fernández-Llamazares, Guillermo, Álvarez-Sala Walther, Luis   +7 more
core   +2 more sources

Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)

Thrombosis Journal, 2023
Background Gynecological cancer is one of the highest risk factors for cancer-associated thrombosis (CAT). Although low-molecular-weight heparin (LMWH) is recommended as an anticoagulant for treating CAT, recent studies have shown that direct oral ...
Tadashi Oride, Kenjiro Sawada, Aasa Shimizu, Yasuto Kinose, Tsuyoshi Takiuchi, Michiko Kodama, Kae Hashimoto, Eiji Kobayashi, Eiji Nakatani, Tadashi Kimura   +9 more
doaj   +1 more source

How we treat bleeding associated with direct oral anticoagulants [PDF]

, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +4 more
core   +1 more source

Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]

, 2020
OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD, Akgün, T, Camm, AJ, Emren, V, Kanat, S, Karacağlar, E, Kepez, A, Kul, Ş, Tülüce, K, Türk, UÖ, Yakar Tülüce, S, Özel, E, Şimşek, E   +12 more
core   +1 more source

Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms [PDF]

, 2016
A growing body of evidence suggests that atrial fibrillation (AF) is associated with myocardial infarction (MI). However, incidence and management of MI in AF is still undefined. METHODS AND RESULTS: We searched MEDLINE via PubMed and Cochrane database
PASTORI, DANIELE, PIGNATELLI, Pasquale, Soliman, Elsayed Z, VIOLI, Francesco   +3 more
core   +1 more source

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]

, 2020
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P, Camm, AJ, Dabrowski, E, Fitzmaurice, DA, Fox, KAA, GARFIELD-AF Investigators, Gersh, BJ, Gibbs, L, Goldhaber, SZ, Goto, S, Haas, S, Kakkar, AK, Luo, K, Misselwitz, F, Pieper, KS, Turpie, AGG, Velentgas, P, Verheugt, FWA   +17 more
core   +2 more sources

Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. [PDF]

PLoS ONE, 2014
Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with non-valvular atrial fibrillation (AF). We conducted an imputed-placebo analysis with estimates of the proportion of warfarin effect preserved by each non
Paolo Verdecchia, Fabio Angeli, Gregory Y H Lip, Gianpaolo Reboldi   +3 more
doaj   +1 more source